Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
TYME - Tyme Technologies Inc
$2.05
0.00(0.00%)5:00:00 AM 1/15/2021
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Stock Chart

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • RSI is at a high level of 75. A high level of RSI indicates the stock is overbought.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/8/2021TYME
    SemiLEDs Reports First Quarter Fiscal Year 2021 Financial Results

    SemiLEDs Corporation (NASDAQ: LEDS), "SemiLEDs" or the "Company," a developer and manufacturer of LED chips and LED components, today announced its financial results for the first quarter of fiscal year 2021, ended November 30, 2020.

    01/6/2021TYME
    SemiLEDs to Announce Fiscal First Quarter 2021 Financial Results on Friday, January 8, 2021

    SemiLEDs Corporation (NASDAQ:LEDS), will report financial results for the 2021 fiscal First quarter ended November 30, 2020 after market close on Friday, January 08, 2021.

    12/23/2020TYME
    Insider Sells Tyme Technologies Shares

    A Form 4 filing filed with the SEC on Wednesday, December 23 showed that Demurjian Michael sold 20,000 shares of Tyme Technologies Inc (NASDAQ:TYME) at an average price of $1.15. The transaction moved the executive's stake in Tyme Technologies Inc. to 25,018,546 shares. Shares of Tyme Technologies traded flat from the previous closing price.Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an i...

    12/15/2020TYME
    We're Keeping An Eye On Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

    12/9/2020TYME
    TYME Announces SM-88 Abstract Selected for Presentation at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an abstract highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer, has been selected for poster presentation at the American Society of Clinical Oncology (ASCO) Virtual 2021 Gastrointestinal Cancers Symposium being held on January 15 - 17, 2021.

    11/30/2020TYME
    TYME Builds Leadership Team with Announcement of New CEO

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that, effective November 24, 2020, Steve Hoffman will remain in the role of Chairman of the board of directors and continue as the Company’s Chief Science Officer, after a successful tenure as Chief Executive Officer since 2015. Richie Cunningham, former Icagen CEO and Boehringer Ingelheim executive, has been appointed as TYME’s next Chief Executive Officer.

    11/27/2020TYME
    Is Tyme Technologies, Inc. (TYME) Going to Burn These Hedge Funds?

    In this article we are going to use hedge fund sentiment as a tool and determine whether Tyme Technologies, Inc. (NASDAQ:TYME) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, […]

    11/12/2020TYME
    TYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating Results

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its second quarter ended September 30, 2020. During the quarter, TYME revealed a potential new therapeutic approach in the fight against COVID-19; was granted orphan drug designation for SM-88 as a potential treatment for patients with pancreatic cancer; expanded its body of peer-reviewed publications on SM-88 and clinical ...